Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00052013
Status:
COMPLETED
Last Update Posted:
2017-03-06
First Post:
2003-01-21
Brief Title:
Treatment of Von Hippel-Lindau VHL-Related Hemangioblastoma With PTK787ZK 222584
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Phase II Open-Label Study of Oral Continuous Once Daily PTK787ZK 222584 in Patients With Von Hippel-Lindau Disease VHL and Hemangioblastoma HB
Status:
COMPLETED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether PTK787ZK 222584 is effective in treating hemangioblastoma of the brain andor retina in patients with von Hippel-Lindau disease The study will also assess safety and tolerability of PTK787ZK 222584 and changes in markers of angiogenesis new blood vessel growth
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None